PRE-TREATMENT IP-10 LEVELS AND IL28B GENOTYPE IN PREDICTION OF SVR IN PRIOR TREATMENT-EXPERIENCED GENOTYPE 1 HCV PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/ RIBAVIRIN IN THE REALIZE STUDY

被引：2
|
作者：
Vijgen, L. [1 ]
Talloen, W. [2 ]
Scholliers, A. [1 ]
Johansson, S. [1 ]
Tuefferd, M. [2 ]
De Meyer, S. [1 ]
Witek, J. [3 ]
Fanning, G. [1 ]
Picchio, G. [3 ]
Pol, S. [4 ,5 ]
Zeuzem, S. [6 ]
Aerssens, J. [1 ]
机构：
[1] Tibotec BVBA, Beerse, Belgium
[2] Janssen Res & Dev, Beerse, Belgium
[3] Janssen Res & Dev LLC, Titusville, NJ USA
[4] Univ Paris 05, INSERM, U1016, Paris, France
[5] Cochin Hosp, Assistance Publ Hop Paris, Paris, France
[6] Goethe Univ Frankfurt, Med Ctr, Frankfurt, Germany
来源：
JOURNAL OF HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
10.1016/S0168-8278(12)61179-9
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1167
引用
收藏
页码：S462 / S462
页数：1
相关论文
共 50 条
  • [41] COMBINATION OF IL28 RS12979860 GENOTYPE WITH PRETREATMENT SERUM IP-10 LEVELS IS THE BEST PREDICTOR OF SVR TO PEGINTERFERON/RIBAVIRIN THERAPY IN CHRONIC HEPATITIS C, GT1 PATIENTS
    Rutter, K.
    Aberle, J.
    Staettermayer, A.
    Beinhardt, S.
    Scherzer, T. M.
    Holzmann, H.
    Hofer, H.
    Steindl-Munda, P.
    Ferenci, P.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S530 - S530
  • [42] Telaprevir in Combination with Peginterferon and Ribavirin in Genotype 1 HCV Treatment-Naive Patients: Final Results of Phase 3 ADVANCE Study
    Ferenci, Peter
    Jacobson, Ira M.
    Adda, Nathalie
    Bengtsson, Leif
    George, Shelley
    Kauffman, Robert
    Zeuzem, Stefan
    SWISS MEDICAL WEEKLY, 2011, 141 : 3S - 3S
  • [43] TELAPREVIR IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN GENOTYPE 1 HCV TREATMENT-NAIVE PATIENTS: FINAL RESULTS OF PHASE 3 ADVANCE STUDY
    Jacobson, Ira M.
    McHutchison, John G.
    Dusheiko, Geoffrey M.
    Di Bisceglie, Adrian M.
    Reddy, Rajender
    Bzowej, Natalie H.
    Marcellin, Patrick
    Muir, Andrew J.
    Bengtsson, Leif
    Dunne, Ann Marie
    Adda, Nathalie
    George, Shelley
    Kauffman, Robert S.
    Zeuzem, Stefan
    HEPATOLOGY, 2010, 52 (04) : 427A - 427A
  • [44] TELAPREVIR IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN GENOTYPE 1 HCV TREATMENT-NAIVE PATIENTS: FINAL RESULTS OF PHASE 3 ADVANCE STUDY
    Dusheiko, G. M.
    Bengtsson, L.
    Adda, N.
    Kauffman, R.
    Jacobson, I. M.
    GUT, 2011, 60 : A32 - A33
  • [45] Sofosbuvir plus Peginterferon/Ribavirin for 12 weeks vs. Sofosbuvir plus Ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the BOSON study
    Pianko, S.
    Cooper, C.
    Brown, A.
    Forton, D.
    Nahass, R.
    George, J.
    Barnes, E.
    Brainard, D.
    Massetto, B.
    Lin, M.
    Mchutchinson, J.
    Subramanian, G. M.
    Agarwal, K.
    Foster, G.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 90 - 90
  • [46] Pre-treatment levels of IP-10 predict response to peginterferon in HBeAg-positive chronic hepatitis B patients
    Sonneveld, Milan J.
    Arends, Pauline
    Boonstra, Andre
    Groothuismink, Zwier M.
    Hansen, Bettina E.
    Janssen, Harry L.
    HEPATOLOGY, 2012, 56 : 386A - 387A
  • [47] INFLUENCE OF HEPATITIS C VIRUS (HCV) GENOTYPE-1 (G1) SUBTYPE, BASELINE VIRAL LOAD AND IL28B GENOTYPE ON PEGINTERFERON (PEG)/RIBAVIRIN (RBV) TREATMENT RESPONSE: RESULTS OF THE IDEAL STUDY
    Rabiee, Atoosa
    Tillmann, Hans L.
    Poordad, F. Fred
    Lawitz, Eric
    Shiffman, Mitchell L.
    Muir, Andrew J.
    Noviello, Stephanie
    Brass, Clifford A.
    Pedicone, Lisa
    Albrecht, Janice K.
    Sulkowski, Mark S.
    Jacobson, Ira M.
    HEPATOLOGY, 2011, 54 : 998A - 999A
  • [48] BASELINE VITAMIN D LEVELS DO NOT INFLUENCE SVR IN PATIENTS WITH CHRONIC HCV GENOTYPE 1 OR 4 INFECTION UNDERGOING PEGINTERFERON/RIBAVIRIN TREATMENT
    Stauber, R. E.
    Scherzer, T.
    Putz-Bankuti, C.
    Matejka, J.
    Spindelboeck, W.
    Zinober, K.
    Beinhardt, S.
    Wehr, E.
    Stojakovic, T.
    Kessler, H. H.
    Ferenci, P.
    Obermayer-Pietsch, B.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S468 - S469
  • [49] Distribution of IL28B and IL10 polymorphisms as genetic predictors of treatment response in Pakistani HCV genotype 3 patients
    Naeemi, Humaira
    Aslam, Rabia
    Raza, Syed Mohsin
    Shahzad, Muhammad Aiman
    Naz, Shagufta
    Manzoor, Sobia
    Khaliq, Saba
    ARCHIVES OF VIROLOGY, 2018, 163 (04) : 997 - 1008
  • [50] Distribution of IL28B and IL10 polymorphisms as genetic predictors of treatment response in Pakistani HCV genotype 3 patients
    Humaira Naeemi
    Rabia Aslam
    Syed Mohsin Raza
    Muhammad Aiman Shahzad
    Shagufta Naz
    Sobia Manzoor
    Saba Khaliq
    Archives of Virology, 2018, 163 : 997 - 1008
12345